New Article information at Pharmaceutical Technology New and updated information from Article listed on en-us New Article information at Pharmaceutical Technology The London Cancer Hub, Sutton The London Cancer Hub for Cancer Research and Treatment in Sutton, London, will be developed by the Institute of Cancer Research (ICR), London, and the London Borough of Sutton in collaboration with The Royal Marsden NHS Foundation Trust, the Greater… Thu, 20 Apr 2017 23:00:00 GMT Narrowing the hunt for nanoparticles Researchers from the Universities of Geneva and Fribourg have devised a rapid screening method to select the most promising nanoparticles for drug development. Lead author Inès Mottas tells Abi Millar how better access to the nanosphere could improve… Wed, 19 Apr 2017 23:00:00 GMT Pharma Technology Focus – Issue 58 In this issue: Promising Alzheimer’s drugs in development, potential applications for the hormone kisspeptin, the cost of failed drug candidates, a new app matching patients to clinical trials, pharma packaging trends, and more. Wed, 19 Apr 2017 13:56:00 GMT Medical and Research Translation (MART) Building, Stony Brook University The construction of the Medical and Research Translation (MART) building at the Stony Brook University (SBU) medical centre campus began in November 2013. Wed, 12 Apr 2017 23:00:00 GMT Michael Uren Biomedical Engineering Research Hub, London Michael Uren Biomedical Engineering Research Hub is a state-of-the-art laboratory and office facility being developed at Imperial College London’s campus in White City, London, UK. Sun, 09 Apr 2017 23:00:00 GMT Pharmaceutical packaging: where should drug companies focus their efforts? The future of pharmaceutical packaging operations is far from straightforward. The Association for Packaging and Processing Technologies reveals where drug companies should be focusing their efforts. Sun, 09 Apr 2017 23:00:00 GMT Alzheimer’s drugs: will 2017 bring better news? No new Alzheimer’s drug has won approval since 2003, but the tide could soon start turning for this previously poorly understood disease. Elly Earls talks to the field’s top researchers to find out what we can expect over the next few years. Wed, 05 Apr 2017 23:00:00 GMT March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn… Sun, 02 Apr 2017 23:00:00 GMT Cancergraph: a desperately needed link between patient and clinical trial While many cancer patients are interested in clinical trials, tough eligibility criteria and a lack of information mean only a fraction actually participate. Help may be at hand, however, thanks to a new mobile app called Cancergraph, thatwhich can m… Fri, 31 Mar 2017 15:21:00 GMT Illuminating drug discovery by mapping all known drugs Innovation requires risks, but what if you could load the odds in your favour? Elly Earls meets cancer scientist Dr Bissan Al-Lazikani to find out how a new map of all existing drugs and their mechanisms of action could help the drug discovery field … Wed, 29 Mar 2017 23:00:00 GMT Pharma Technology Focus – Issue 57 In this issue: Japan’s pharma industry looks abroad, Trump’s plans for US drug manufacturing, unlocking regenerative medicine, the medical benefits of turmeric, the dangers posed by first-in-human drug trials, and more. Wed, 22 Mar 2017 14:44:00 GMT Knight Cancer Institute Research Building, Oregon Oregon Health & Science University (OHSU)'s Knight Cancer Institute commenced construction of a new research building at South Waterfront district in south-west Portland, Oregon. Tue, 21 Mar 2017 00:00:00 GMT Turning to turmeric: exciting drug candidate or another dead end? Turmeric has long been used as a natural remedy, and many studies seem to back that up. However, a recent review has suggested that many of the apparent benefits are bad science. So what does that mean for turmeric research, and particularly for the … Mon, 20 Mar 2017 00:00:00 GMT Rosalind Franklin University’s Innovation and Research Park, Chicago Rosalind Franklin University (RFU) has announced plans for the construction of a new innovation and research park at 3333 Green Bay road in the university's North Chicago campus. Thu, 16 Mar 2017 00:00:00 GMT BlueRock Therapeutics: Ontario’s home-grown stem cell contender New Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing from Bayer and Versant Ventures. What stem cell-based therapies is the company working on to justify this investor … Tue, 14 Mar 2017 00:00:00 GMT Takeda turns its focus overseas Japanese pharmaceutical company Takeda has bought Ariad Pharmaceuticals for around $5.2bn. Deals of this kind are becoming increasingly prevalent, as the Japanese pharma industry sets its sights beyond the traditional domestic market. Abi Millar repo… Mon, 13 Mar 2017 00:00:00 GMT Learning from tragedy: safety and dosing in first-in-human trials The Rennes clinical trial disaster in January last year highlights the dangers posed by first-in-human trials of high-risk drug candidates, with dosing strategies coming under the spotlight. What makes early-stage trials go wrong, and how can dosing … Wed, 08 Mar 2017 00:00:00 GMT February's top stories: Takeda's $5.2bn acquisition, Sanofi €270m cell culture facility investment Takeda completed its acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn, while Sanofi and Lonza invested €270m in a new mammalian cell culture facility in Switzerland. wraps up the key headlines fr… Tue, 07 Mar 2017 00:00:00 GMT Is US drug manufacturing homeward bound? New US President Donald Trump has indicated that he wants to reform drug manufacturing for the US market, emphasising domestic production rather than outsourcing to plants abroad. Abi Millar looks into the US’s current pharma manufacturing and drug s… Mon, 06 Mar 2017 00:00:00 GMT Fresenius Kabi's Pharmaceutical Manufacturing Facility Expansion, Melrose Park, Illinois German pharmaceutical company Fresenius Kabi announced a proposal to expand its pharmaceutical manufacturing capabilities at Melrose Park village site in Illinois, US. Fri, 03 Mar 2017 00:00:00 GMT